Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics (LON:IDHC) and Proteome Sciences (LON:PRM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.

Do institutionals and insiders have more ownership in IDHC or PRM?

43.0% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 23.0% of Proteome Sciences shares are held by institutional investors. 34.0% of Integrated Diagnostics shares are held by company insiders. Comparatively, 19.5% of Proteome Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media favor IDHC or PRM?

In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company	Overall Sentiment
Integrated Diagnostics	Neutral
Proteome Sciences	Neutral

Does the MarketBeat Community favor IDHC or PRM?

Proteome Sciences received 106 more outperform votes than Integrated Diagnostics when rated by MarketBeat users. However, 65.12% of users gave Integrated Diagnostics an outperform vote while only 57.04% of users gave Proteome Sciences an outperform vote.

Company	Underperform	Outperform
Integrated Diagnostics	Outperform Votes 56 65.12%	Underperform Votes 30 34.88%
Proteome Sciences	Outperform Votes 162 57.04%	Underperform Votes 122 42.96%

Which has more risk and volatility, IDHC or PRM?

Integrated Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Proteome Sciences has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.

Which has preferable earnings and valuation, IDHC or PRM?

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated Diagnostics	£4.75B	0.00	£817.28M	£0.03	15.00
Proteome Sciences	£4.04M	2.24	-£4.08M	-£0.01	-307.20

Is IDHC or PRM more profitable?

Integrated Diagnostics has a net margin of 17.21% compared to Proteome Sciences' net margin of -101.07%. Integrated Diagnostics' return on equity of 23.03% beat Proteome Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integrated Diagnostics	17.21%	23.03%	9.69%
Proteome Sciences	-101.07%	N/A	-19.25%

Summary

Integrated Diagnostics beats Proteome Sciences on 11 of the 13 factors compared between the two stocks.